FDA Grants Full Approval to Tecelra® for Advanced Synovial Sarcoma
The U.S. Food and Drug Administration (FDA) has granted full approval to Tecelra® (afamitresgene autoleucel, afami-cel) for eligible patients 12 years of age and older with synovial sarcoma that cannot be removed with surgery or has spread to other parts of the body and has progressed following chemotherapy.
Tecelra first received accelerated approval in 2024. Full approval means the FDA has reviewed additional clinical evidence confirming the treatment’s benefits, moving it from accelerated to traditional approval. The expanded approval also includes adolescents as young as 12 years of age, making Tecelra the first engineered T-cell therapy approved for children with a solid tumor.
Tecelra is a personalized immune cell therapy that uses a patient’s own T cells to recognize and attack cancer. A patient’s T cells are collected and genetically modified to recognize a protein called MAGE-A4 that is found on some synovial sarcoma tumors. The modified cells are then returned to the patient, where they help the immune system identify and destroy cancer cells. Not every patient with synovial sarcoma is eligible for this treatment. Patients must have tumors that express the MAGE-A4 protein and have a specific inherited immune system marker called HLA-A*02. Testing for both biomarkers is required before treatment can be considered.
The FDA based its decision on results from the Phase 2 SPEARHEAD-1 trial. As with other cellular therapies, Tecelra carries important risks, including cytokine release syndrome (CRS), and treatment requires close monitoring at a specialized treatment center following infusion.
What This Means for Patients
Full FDA approval provides greater confidence that this therapy offers meaningful benefit for appropriately selected patients with advanced synovial sarcoma. It also reinforces the growing importance of biomarker testing, since determining both MAGE-A4 expression and HLA type is essential to identifying patients who may benefit. Patients with advanced synovial sarcoma who have not undergone this testing should consider discussing it with their healthcare team. While not everyone will be eligible for Tecelra, this approval represents another important step forward in expanding treatment options for people living with synovial sarcoma.